Topics:

Rheumatology Network

Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?

Recent Content

Prompt action by Alabama rheumatologists has caused Blue Cross Blue Shield to rethink a policy denying all claims for injections into knees with osteoarthritis. But a similar "ban" on hyaluronic acid in neighboring Florida takes effect today.

A major disconnect in psoriatic arthritis treatment: Assessment tools and guidelines largely ignore flares. But over half of patients in two new surveys report severe flares or completely unremitting disease. Both are linked to poor outcomes.

scleroderma

A general overview of the fibrosis process discusses mechanisms and cell pathways in brief while focusing on clinical issues.

Although studies of ultrasound diagnosis for gout are scarce, the authors of two reviews maintain the evidence is good that it is a useful option--and may be leading to some revisions in the way the condition is detectedl.

About 30% of rheumatologists don't pre-test patients for hepatitis B before prescribing immunosuppressant medications. These authors offer new guidance for screening.

(AAOS2015) Evidence from large insurance databases shows that knee replacement often quickly follows arthroscopy or injections. It would make (economic and clinical) sense to go straight to surgery, the researchers contend.

Tech Tips: In Part I, Dr. Bhana gave advice about sorting through the barrage of clinical journal articles that rheumatologists face every month. Here, in Part II, he shows how to save and file your choices for easy access in the future.

By clicking Accept, you agree to become a member of the UBM Medica Community.